3 ASX 200 shares named as buys

Here are three buy-rated ASX 200 shares to look at…

| More on:
asx buy

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking for some ASX 200 shares to add to your portfolio? Then take a look at the three listed below.

Here's why they are rated as buys currently:

Aristocrat Leisure Limited (ASX: ALL)

The first ASX 200 share to look at is Aristocrat Leisure. It is one of the world's leading gaming technology companies. The last 12 months have been difficult for Aristocrat but it has bounced back strongly and looks well-positioned for growth. Especially now both its pokie machine and digital businesses are pulling together again. Citi is a fan of the company. It has a buy rating and $46.00 price target on its shares.

REA Group Limited (ASX: REA)

REA Group could be an ASX 200 share to consider. It is the leading player in real estate listings in the Australian market. This is a great position to be right now thanks to the housing market boom, which is underpinning solid listings growth. In addition to this, cost cutting, new revenue streams, price increases, and acquisitions look set to give its sales and earnings a boost in the coming years. Goldman Sachs is very bullish on REA Group. It recently put a buy rating and $198.00 price target on its shares.

ResMed Inc. (ASX: RMD)

Another ASX 200 share to look at is ResMed. It is one of the world's leading medical device companies with a focus on sleep disorders. ResMed has been tipped for further strong growth over the 2020s thanks to its enormous addressable market, its industry-leading technology, and its digital health ecosystem. In respect to the latter, the company's investment in digital health have given it an advantage over much of the competition and puts it in a strong position to benefit from the shift to home healthcare. Macquarie currently has an outperform rating and $34.85 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended REA Group Limited and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

Two plants grow in jars filled with coins.
Growth Shares

3 ASX 200 growth stocks up more than 100% in 1 year that could charge higher

It's been a memorable year for shareholders of these 3 companies.

Read more »

Afterpay share price a happy shopper with a wide mouthed smile holds multiple shopping bags up around her shoulders.
Growth Shares

The pros and cons of buying Zip shares in June

Should investors buy now or wait until later?

Read more »

A smiling woman holds a Facebook like sign above her head.
Growth Shares

3 ASX growth shares I'd buy for the next 10 years

Let's see why these shares could be top picks for the long term.

Read more »

wheelchair user in an office talking on mobile phone
Growth Shares

Why I'd buy this ASX growth share instantly

I’m calling on this stock to deliver strong returns.

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.
Growth Shares

2 ASX growth shares to buy in June: experts

These businesses have strong growth potential.

Read more »

Rocket powering up and symbolising a rising share price.
Growth Shares

Buy these stellar ASX growth shares with $1,000

Analysts think these shares would be top buys right now.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Growth Shares

These ASX growth shares could rise 18% to 30%

Let's see which shares are being tipped to rocket.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Growth Shares

Goldman Sachs tips this ASX 200 growth stock to rise 35%

Let's see what the broker is saying about this growing company.

Read more »